Ticagrelor Dose 1a + Dose 2a + Ticagrelor Dose 1b + Dose 2b
Phase 2CompletedDevelopment Stage
Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
Sep 11, 2014 → Feb 27, 2017
About Ticagrelor Dose 1a + Dose 2a + Ticagrelor Dose 1b + Dose 2b
Ticagrelor Dose 1a + Dose 2a + Ticagrelor Dose 1b + Dose 2b is a phase 2 stage product being developed by AstraZeneca for Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02214121. Target conditions include Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease.
What happened to similar drugs?
0 of 2 similar drugs in Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02214121 | Phase 2 | Completed |
Competing Products
2 competing products in Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Acetylsalicylic acid (Fast release Aspirin, BAY1019036) + Acetylsalicylic Acid (Aspirin, BAYE4465) + Placebo | Bayer | Phase 3 | 37 |
| Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036) + Acetylsalicyclic acid (Aspirin, BAYE4465) + Placebo | Bayer | Phase 3 | 37 |